Simulations Plus Inc
NASDAQ:SLP
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
27.22
50.95
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Simulations Plus Inc
Simulations Plus Inc
Research & Development
Simulations Plus Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Simulations Plus Inc
NASDAQ:SLP
|
Research & Development
-$5.8m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-20%
|
|
|
Veeva Systems Inc
NYSE:VEEV
|
Research & Development
-$664m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
-35%
|
|
|
Inspire Medical Systems Inc
NYSE:INSP
|
Research & Development
-$114.8m
|
CAGR 3-Years
-49%
|
CAGR 5-Years
-59%
|
CAGR 10-Years
N/A
|
|
|
Doximity Inc
NYSE:DOCS
|
Research & Development
-$82m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
N/A
|
|
|
Omnicell Inc
NASDAQ:OMCL
|
Research & Development
-$87.5m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-12%
|
|
|
W
|
Waystar Holding Corp
NASDAQ:WAY
|
Research & Development
-$35.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Simulations Plus Inc
Glance View
Simulations Plus, Inc. provides modeling and simulation software and consulting services supporting drug discovery, development research and regulatory submissions. The company is headquartered in Lancaster, California and currently employs 135 full-time employees. The company provides prediction of properties of molecules utilizing artificial-intelligence- and machine-learning-based technology. The company also provides consulting services ranging from early drug discovery through preclinical and clinical trial development to regulatory submissions in support of product approval. The company offers 11 software products for pharmaceutical research and development, which includes GastroPlus, DDDPlus, MembranePlus, DILIsym, NAFLDsym, ADMET Predictor, MedChem Designer, MedChem Studio, PKPlus, KIWI and Monolix Suite of products through Lixoft. Its software and consulting services are provided to pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies and to academic and regulatory agencies worldwide for use in the conduct of industry-based research. Cognigen Corporation, DILIsym Services, Inc. and Lixoft are its subsidiaries.
See Also
What is Simulations Plus Inc's Research & Development?
Research & Development
-5.8m
USD
Based on the financial report for Aug 31, 2024, Simulations Plus Inc's Research & Development amounts to -5.8m USD.
What is Simulations Plus Inc's Research & Development growth rate?
Research & Development CAGR 10Y
-20%
Over the last year, the Research & Development growth was -28%. The average annual Research & Development growth rates for Simulations Plus Inc have been -12% over the past three years , -18% over the past five years , and -20% over the past ten years .
You don't have any saved screeners yet
